CBRT20074 / A071701 / Michael White
Basic Study Information
Purpose:Location: University of Rochester
This phase II trial studies how well genetic testing works in guiding treatment for
patients with solid tumors that have spread to the brain. Several genes have been
found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K.
Medications that target these genes such as abemaciclib, paxalisib, and entrectinib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Genetic testing may help doctors tailor treatment for each mutation.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search